The PennZone

WEXFORD, Pa., Dec. 27, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced its plans to proceed with a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The decision was made following authorization by the company's board of directors and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40.

The reverse stock split, also known as a consolidation, will see every 20 shares of the company's outstanding and issued common stock converted into one share. This move is intended to help Coeptis meet the minimum bid price requirement necessary to maintain its listing on the Nasdaq Capital Market. Under Nasdaq rules, listed companies must maintain a minimum bid price of at least $1.00 per share.

The decision to proceed with the reverse split was approved by Coeptis' stockholders at the company's Annual Stockholder's Meeting on December 18, 2024. Following this meeting, the Board established the reverse split ratio and authorized it to proceed.

More on The PennZone

• Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
• Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
• J. Wes Seeks Jazz Musicians, Vocalists and Bands for Philadelphia Live Music Event
• NECP Promotes Chertova to Senior Business Analyst
• Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth

The first day of trading on a post-split basis on the Nasdaq Capital Market will be at market open on December 31, 2024. Upon the effective date of the Reverse Split, any fractional shares for record holders that would have resulted from the split will be rounded up to the next whole number. This will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

Continental Stock Transfer has been appointed as the exchange agent and transfer agent for the reverse stock split. They will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new ones if they wish to do so. However, those who hold their shares in brokerage accounts or "street name" are not required to take any action.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. The company's product portfolio includes assets licensed from Deverra Therapeutics and the University of Pittsburgh. It is also developing a universal CAR technology in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute.

More on The PennZone

• Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
• Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
• New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
• Beyond the Odds: BetQL Combines Sharp Money Trends and Real Time Odds to Help Bettors Find Value
• Mark Schork and Terri Smith Honored by Philadelphia Bar Association as 'Bar Stars'

The Company's CEO expressed excitement about the potential of their innovative cell therapy platforms to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis is headquartered in Wexford, PA.

Investors are advised to exercise caution when considering any investment in Coeptis Therapeutics Holdings, Inc. as there are inherent risks associated with investing in biopharmaceutical companies. For more information on Coeptis and its developments, visit https://coeptistx.com.

---

Show All News | Disclaimer | Report Violation